Tougher induction chemo for CLL better for later quality of life
According to findings published in Leukemia & Lymphoma, patients diagnosed with chronic lymphocytic leukemia (CLL) can achieve a good quality of life after they have fully completed treatment. This is important because CLL affects elderly patients chiefly, meaning that side effects and toxicity can have especially damaging effects.
The findings come from a trial of 777 CLL patients tracked for five years. Patients received either:
-- Fludarabine
-- Chlorambucil
-- Fludarabine and cyclophosphamide (FC)
Currently, fludarabine and cyclophosphamide plus Rituxan is considered the standard of care in this patient population, but concerns over difficult to manage side effects has had an impact on quality of life.
What researchers learned is that while FC therapy was indeed more harsh, this only remained true during treatment. Over the long run, patients receiving this treatment reported the same measures of quality of life as people of the same age and sex without cancer.
Source: Medical News Today
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
